Microvast Holdings announces departure of chief financial officer
Director David Dalvey reported selling shares of Celcuity Inc. (NASDAQ:CELC) on July 28, 2025, according to a Form 4 filing with the Securities and Exchange Commission. The sales, which totaled $4,818,369, were executed at prices ranging from $43.2974 to $46.0501. The transactions come as InvestingPro data shows the stock has surged over 174% in the past week, with technical indicators suggesting overbought conditions. The company currently maintains a market capitalization of $1.56 billion.
Dalvey sold 3,137 shares of common stock at a weighted average price of $44.3646, 4,163 shares at a weighted average price of $45.2423 and 2,025 shares at a weighted average price of $46.0501. These transactions were directly owned. Trading near its 52-week high of $46.42, the stock currently trades at a significant price-to-book multiple of 18.1x.
In addition, 57,044 shares were sold at a weighted average price of $43.2974, 22,377 shares at a weighted average price of $44.3580, 16,438 shares at a weighted average price of $45.2886 and 4,141 shares at a price of $46.05. These transactions were indirectly owned by Brightstone Venture Capital Fund, LP, where Dalvey serves as the General Partner.
These sales were executed under a pre-arranged Rule 10b5-1 trading plan adopted on December 13, 2024. Following the transactions, Dalvey directly owns 0 shares and indirectly owns 125,000 shares through Brightstone Venture Capital Fund, LP.
In other recent news, Celcuity Inc. announced the pricing of two separate offerings, including $175 million in convertible senior notes due 2031 and a public offering of 1,836,842 shares of common stock at $38.00 per share. The company also offered pre-funded warrants to purchase up to 400,000 shares at $37.999 per warrant, with underwriters having a 30-day option to purchase additional convertible notes worth $26.25 million and up to 335,526 additional shares. H.C. Wainwright raised its price target for Celcuity to $50.00 from $27.00, maintaining a Buy rating after the company reported positive Phase 3 trial results. These results showed that their breast cancer drug, gedatolisib, significantly reduced the risk of disease progression or death in patients with advanced breast cancer. The trial demonstrated that the gedatolisib triplet therapy reduced the risk by 76% compared to fulvestrant alone. Celcuity had previously announced proposed public offerings totaling $225 million, consisting of $150 million in convertible senior notes and $75 million in common stock. The company plans to grant underwriters 30-day options to purchase additional convertible notes and common stock to cover potential over-allotments. These developments come as Celcuity continues to focus on its targeted cancer therapies.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.